What the evidence says about cannabis for multiple sclerosis symptoms
Cannabinoids show some promise for MS-related spasticity and pain, but clinical trial evidence remains limited and most support comes from preclinical or animal studies.
Quick Facts
What This Study Found
The endocannabinoid system plays a documented role in demyelination and neuroinflammation. Clinical data, primarily from nabiximols (Sativex), suggests modest benefit for spasticity, but evidence for other MS symptoms is thin.
Key Numbers
Up to 80% of MS patients experience disabling symptoms. Nabiximols (THC:CBD 1:1 spray) is the most studied cannabinoid product for MS spasticity. Clinical trials remain relatively few compared to the volume of preclinical research.
How They Did This
Narrative review of preclinical studies on cannabinoids in experimental demyelination models and clinical trials examining cannabinoid therapies for MS symptoms including spasticity, pain, and bladder dysfunction.
Why This Research Matters
Up to 80% of people with MS deal with disabling symptoms, and first-line treatments carry significant side effects. Cannabinoids represent an area of active patient interest that needs rigorous clinical evaluation.
The Bigger Picture
MS patients are already using cannabis products in large numbers. The gap between patient demand and clinical evidence creates a situation where people are essentially self-experimenting without reliable dosing or formulation guidance.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. Heavy reliance on animal and preclinical models. Clinical trial data limited primarily to nabiximols. Does not address long-term safety of cannabinoid use in MS populations.
Questions This Raises
- ?Which specific cannabinoid formulations and ratios would be most effective for different MS symptoms?
- ?Could cannabinoids modify disease progression, not just symptoms?
Trust & Context
- Key Stat:
- Up to 80% of MS patients experience disabling symptoms like spasticity and pain
- Evidence Grade:
- Narrative review drawing primarily from preclinical models with limited clinical trial evidence, mostly focused on one product (nabiximols).
- Study Age:
- Published 2022.
- Original Title:
- Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice-A Review.
- Published In:
- American journal of therapeutics, 30(3), e220-e231 (2023)
- Authors:
- Sirbu, Carmen-Adella, Georgescu, Ruxandra, Pleşa, Florentina Cristina, Paunescu, Alina, Marilena Ţânţu, Monica, Nicolae, Alina Crenguţa, Caloianu, Ionut, Mitrica, Marian
- Database ID:
- RTHC-04948
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does cannabis help with MS spasticity?
Nabiximols, a prescription spray containing equal parts THC and CBD, has the most clinical evidence for MS-related spasticity. Some patients report benefit, though trial results are mixed and effect sizes tend to be modest.
Why is there so little clinical evidence for cannabis in MS?
Most research has been done in animal models of demyelination rather than in people with MS. Regulatory barriers, variable cannabis formulations, and the difficulty of blinding participants in cannabis trials all contribute to the limited clinical data.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04948APA
Sirbu, Carmen-Adella; Georgescu, Ruxandra; Pleşa, Florentina Cristina; Paunescu, Alina; Marilena Ţânţu, Monica; Nicolae, Alina Crenguţa; Caloianu, Ionut; Mitrica, Marian. (2023). Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice-A Review.. American journal of therapeutics, 30(3), e220-e231. https://doi.org/10.1097/MJT.0000000000001568
MLA
Sirbu, Carmen-Adella, et al. "Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice-A Review.." American journal of therapeutics, 2023. https://doi.org/10.1097/MJT.0000000000001568
RethinkTHC
RethinkTHC Research Database. "Cannabis and Cannabinoids in Multiple Sclerosis: From Experi..." RTHC-04948. Retrieved from https://rethinkthc.com/research/sirbu-2023-cannabis-and-cannabinoids-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.